CN101301455A - Chinese medicine compound turmeric rhizome solid dispersion for treating hyperlipemia - Google Patents
Chinese medicine compound turmeric rhizome solid dispersion for treating hyperlipemia Download PDFInfo
- Publication number
- CN101301455A CN101301455A CNA2008101069687A CN200810106968A CN101301455A CN 101301455 A CN101301455 A CN 101301455A CN A2008101069687 A CNA2008101069687 A CN A2008101069687A CN 200810106968 A CN200810106968 A CN 200810106968A CN 101301455 A CN101301455 A CN 101301455A
- Authority
- CN
- China
- Prior art keywords
- solid dispersion
- curcumin
- compound turmeric
- turmeric rhizome
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention discloses a Chinese traditional medicine compound solid dispersion made of curcumin, piperine and water soluble polymer carrier, wherein the mass ratio between curcumin and piperine is between 1 to 1 and 500 to 1, and the mass ratio between curcumin and the water soluble polymer carrier is between 1 to 1 and 1 to 4. The Chinese traditional medicine compound solid dispersion adopts high molecular material as the carrier and is prepared through a solvent method, thereby obviously improving the digestion velocity, solubility and bioavailability of curcumin. The prepared compound solid dispersion which has good effect on reducing triglyceride and cholesterol without any obvious toxic and side effect has important applications to the preparation of medicines or health products for curing hyperlipemia.
Description
Technical field
The invention belongs to the Chinese medicine class, relate in particular to the Chinese medicine compound turmeric rhizome solid dispersion of treatment hyperlipemia.
Background technology
Hyperlipemia is that lipid level is higher than normal a kind of disease in the blood plasma owing to lipid metabolism causes unusually, is to cause atherosclerotic risk factor.The arteriosclerosis of heart and brain can cause diseases such as coronary heart disease, angina pectoris, myocardial infarction and cerebrovascular accident; The blood capillary sclerosis of kidney can cause renal failure, thereby cause intractable hypertension and uremia; Blood fat is too high also can to cause fatty liver, and severe patient can cause liver cirrhosis.
Clinical blood lipid-lowering medicine commonly used mainly contains: 1, fibrate its mainly act as triglyceride reducing and cholesterol, but untoward reaction such as nauseating, abdominal distention, diarrhoea, leukopenia are often arranged; 2, Statins is based on cholesterol reducing, and effect for reducing fat is strong, and is rapid-action, but headache, insomnia are arranged, untoward reaction such as feel sick; 3, the effect of nicotinic acid class reduction serum triglycerides is stronger, but easily produces skin erythema, hotness, pruritus; Mild adverse effects such as 4, unsaturated fatty acid and phospholipid effect for reducing blood fat are gentle, and xerostomia appears in a few patients, feel sick; 5, pantethine can obviously improve lipid metabolism, and certain effect for reducing fat is arranged, but can cause diarrhoea, inappetence; 6, propylene glycol alginate sodium sulfate has the effect that reduces blood viscosity, blood vessel dilating, blood fat reducing, and untoward reaction has epigastric discomfort, dizzy cardiopalmus etc.; 7, hormones mainly act as cholesterol reducing, but side effect is more obvious.
From present case, also do not conform with very much the fat-reducing medicament of physiological requirement.Most lipid lowerers only have short term efficacy, and life-time service then tangible side reaction can occur.
Summary of the invention
Purpose of the present invention is exactly in order to address the above problem, and a kind of Chinese medicine compound turmeric rhizome solid dispersion for the treatment of hyperlipemia safely and efficiently is provided.
A kind of Chinese medicine compound turmeric rhizome solid dispersion for the treatment of hyperlipemia, make by curcumin, piperine and water soluble polymer carrier, wherein the mass ratio of curcumin and piperine is 1: 1～500: 1, and the mass ratio of curcumin and water soluble polymer carrier is 1: 1～1: 4.
The manufacture method of above-mentioned Chinese medicine compound turmeric rhizome solid dispersion, by above proportioning, get curcumin, piperine and water soluble polymer carrier and be dissolved in organic solvent, under 25～75 ℃ of distilling under reduced pressure, remove most of organic solvent to becoming pasty state, pour in the stainless steel disc rapidly, 40～80 ℃ of following vacuum drying oven oven dry, obtain compound turmeric rhizome solid dispersion with the pulverizer pulverizing.
Above-mentioned organic solvent is ethanol, isopropyl alcohol, propanol or ethyl acetate.
Above-mentioned water soluble polymer carrier is polyvinylpyrrolidone (PVP), Polyethylene Glycol (PEG) 4000 and 6000, carbamide, citric acid, xylitol, chitosan (CS).
Compound turmeric rhizome solid dispersion provided by the invention can cooperate with the medicament filler of normal conventional, makes through conventional method; Can make suitable dosage form as required, as injection, tablet, powder, granule, capsule, oral liquid or suppository etc.Usually use with oral way, can certainly adopt other administering mode; Its, using dosage was generally about 0.001～500000 milligram every day, and adult's usual amounts is 0.002～200000 milligram, and the most frequently used dosage is 0.01～50000 milligram.Once a day or divide for several times and use.
Beneficial effect of the present invention: the present invention is carrier with the water-soluble high-molecular material, adopts solvent method to prepare compound turmeric rhizome solid dispersion, has significantly improved dissolution rate and the dissolubility and the bioavailability of curcumin.Prepared compound turmeric rhizome solid dispersion, triglyceride reducing and cholesterol effect are fine, no obvious toxic and side effects, being used for the treatment of in the medicine of hyperlipemia or the health product in preparation has important use.And preparation method is simple, and cost is low.
Description of drawings
The UV scanning figure of Fig. 1 curcumin reference substance ethanol solution;
Fig. 2 compound turmeric-PVP solid dispersion accumulation stripping percentage diagram;
Fig. 3 compound turmeric-CS solid dispersion accumulation stripping percentage diagram;
Fig. 4 curcumin TLC chromatogram;
Fig. 5 curcumin reference substance chromatogram (425nm);
Fig. 6 compound turmeric rhizome solid dispersion chromatogram (425nm);
Fig. 7 negative control chromatogram (425nm);
Fig. 8 piperine reference substance chromatogram (343nm);
Fig. 9 compound turmeric rhizome solid dispersion chromatogram (343nm);
Figure 10 negative control chromatogram (343nm);
Figure 11,12 compound turmeric rhizome solid dispersions cause the influence of mice hyperlipemia to Triton WR-1339;
Figure 13,14 compound turmeric rhizome solid dispersions are to the influence of rat bait hyperlipemia.
The specific embodiment
The preparation of embodiment 1 compound turmeric rhizome solid dispersion
1.1 medicine, reagent and instrument
Curcumin crude drug (Sichuan gold Radix Curcumae scientific and technological development company limited); Piperine crude drug (Zhun-ao Science and Technology Development Co., Ltd., Hainan); Polyvinylpyrrolidone K30 (Shanghai chemical reagents corporation of Chinese Medicine group, PVP); Chitosan (the prosperous butterfly chitin in Dalian company, CS); Dehydrated alcohol (analytical pure, Guangzhou Chemical Reagent Factory) Rotary Evaporators (Tianjin glass apparatus maker); DZF-2001 type vacuum drying oven (Shanghai experimental apparatus factory)
1.2 the preparation of compound turmeric-PVP solid dispersion
Select for use dehydrated alcohol to make solvent, adopt the solvent method preparation.Get curcumin 100g, piperine 10g and PVPK30 with 3 kinds of ratios (1: 0.1: 1,1: 0.1: 2,1: 0.1: 3) be dissolved in an amount of ethanol, be stirred to the clear and bright dissolving fully that makes, with three kinds of abundant mix homogeneously of solution, remove most of ethanol to becoming pasty state in 40 ℃ of following reduction vaporizations, pour into rapidly in the stainless steel disc, put (50 ℃) dry 24h in the vacuum drying oven, pulverize porphyrize and cross 80 mesh sieves, make compound turmeric rhizome solid dispersion, put in the exsiccator and preserve.
1.3 the preparation of compound turmeric-CS solid dispersion
Select for use dehydrated alcohol to make solvent, adopt the solvent method preparation.Get curcumin 100g, piperine 10g and CS with 3 kinds of ratios (1: 0.1: 1,1: 0.1: 2,1: 0.1: 3) be dissolved in an amount of ethanol, be stirred to the clear and bright dissolving fully that makes, with three kinds of abundant mix homogeneously of solution, remove most of ethanol to becoming pasty state in 40 ℃ of following reduction vaporizations, pour into rapidly in the stainless steel disc, put (50 ℃) dry 24h in the vacuum drying oven, pulverize porphyrize and cross 80 mesh sieves, make compound turmeric rhizome solid dispersion, put in the exsiccator and preserve.
Curcumin dissolution determination in embodiment 2 compound turmeric rhizome solid dispersions
2.1 instrument
ZRS-8G type intelligence digestion instrument (Radio Factory of Tianjin Univ.); UV-2501PC ultraviolet spectrophotometer (day island proper Tianjin)
2.2 it is an amount of that the selection precision of maximum absorption wavelength takes by weighing the curcumin standard substance, makes the solution of about 4mg/L with dissolve with ethanol; Other gets an amount of PVPK30, CS, uses dissolve with ethanol respectively, in the scanning of 200～500nm place, does blank with dehydrated alcohol above-mentioned 3 kinds of solution.
As shown in Figure 1, the result shows that the curcumin alcoholic solution has absorption maximum at the 425nm place, and PVPK30 and CS are noiseless at this wavelength place, so select 425nm as measuring wavelength.
2.3 the preparation of standard curve is accurately drawn curcumin reference substance solution (0.5g/mL) 20,40,60,80,100 μ L respectively and be diluted to scale with simulated gastric fluid-ethanol (65: 35) in the 10mL volumetric flask, shakes up.With simulated gastric fluid-ethanol (65: 35) is the blank trap of surveying at the 425nm place, and (A) calculates regression equation to curcumin concentration with trap: A=0.1449C+0.0817 r=0.9962, the range of linearity is 1.0～5.0mg/L.
2.4 dissolution determination adopts the oar method of Chinese Pharmacopoeia regulation to measure, and is dissolution medium with simulated gastric fluid-ethanol (65: 35), rotating speed 100r/min, temperature (37 ± 0.5) ℃.Precision takes by weighing the solid dispersion of curcumin crude drug, compound turmeric physical mixture and various ratios, uniformly dispersing is on the medium liquid level, when drug powder contact solution, pick up counting, respectively at 5,10,20,30,45,60 minutes, each 5mL that takes a sample (adding synthermal equivalent dissolution medium simultaneously), use the filtering with microporous membrane of 0.8 μ m immediately, discard filtrate just, subsequent filtrate (dilution in case of necessity) is measured trap A at the 425nm place, and substitution standard curve equation is obtained the accumulation stripping percentage rate of different samples at different time.Measurement result sees Table 1, table 2.
Table 1 compound turmeric-PVP solid dispersion dissolution in vitro experiment
Table 2 compound turmeric-CS solid dispersion dissolution in vitro experiment
2.5 result
As Fig. 2, shown in Figure 3, from the result of dissolution as can be seen, curcumin and two kinds of carriers (PVPK30, CS) make solid dispersion after dissolution all improve.PVP K30 is as carrier, and along with the ratio of carrier in solid dispersion increases, dissolution also increases, and the dissolution rate of compound turmeric-PVP (1: 3) solid dispersion is the fastest, 5min stripping curcumin＞70%; Compound turmeric-CS solid dispersion all is significantly improved than the dissolution rate of curcumin crude drug and compound turmeric physical mixture, but dissolution rate does not increase along with the increase of CS ratio, in the stripping starting stage, increase along with the CS ratio, dissolution rate slows down, and may be that tool is a bit sticky because CS forms gel under acid condition, drug powder flocks together, and has hindered the stripping of medicine.
The discriminating and the assay of embodiment 3 compound turmeric rhizome solid dispersions
3.1 medicine, reagent and instrument
Curcumin crude drug (Sichuan gold Radix Curcumae scientific and technological development company limited); Piperine crude drug (Zhun-ao Science and Technology Development Co., Ltd., Hainan); Curcumin standard substance (Nat'l Pharmaceutical ﹠ Biological Products Control Institute, lot number: 110823-980); Piperine standard substance (Nat'l Pharmaceutical ﹠ Biological Products Control Institute, lot number: 110775-200); Polyvinylpyrrolidone K30 (Shanghai chemical reagents corporation of Chinese Medicine group, PVP); Acetonitrile (Merk company, chromatographically pure); Compound turmeric-PVP solid dispersion (self-control).
Agilent1100 high performance liquid chromatograph (U.S. Agilent company); The full-automatic point sample instrument of CAMAG Automatic TLCSampler 4 types (Switzerland's card agate); CAMAG REPROSTAR 3 thin layer digital imaging systems (Switzerland's card agate).
3.2 the thin layer of curcumin is differentiated in compound turmeric-PVP solid dispersion
Adopt thin layer chromatography, development system is chloroform-methanol-formic acid (96: 4: 1), curcumin crude drug, compound turmeric-PVP solid dispersion, compound turmeric physical mixture, curcumin reference substance, PVPK30 are launched on lamellae, its thin-layer chromatogram as shown in Figure 4,1 among the figure, 2,3,4,5,6 respectively is expressed as follows:
1～2 compound turmeric-PVP solid dispersion
3 compound turmeric physical mixtures
4 curcumin crude drug
5 curcumin reference substances
6PVPK30
The result shows, the Rf value unanimity of curcumin crude drug, compound turmeric rhizome solid dispersion, compound turmeric physical mixture, curcumin reference substance illustrates that the curcumin structure in the compound turmeric rhizome solid dispersion does not change.
3.3 the assay of curcumin and piperine in the compound turmeric rhizome solid dispersion
Adopt high performance liquid chromatography, chromatographic condition is as follows:
Chromatographic column: Zorbax Eclipse XDB-C8 post (4.6 * 150mm, 5 μ m); Detect wavelength: 425nm, 343nm; Flow velocity: 0.7mLmin-1; Column temperature: 20 ℃; Sample size: 10 μ L; Mobile phase: acetonitrile-3% phosphate aqueous solution (40: 60).Theoretical cam curve is calculated by curcumin peak and piperine peak should be not less than 3000.Precision takes by weighing the curcumin reference substance and the piperine reference substance is an amount of respectively, adds that dissolve with methanol is mixed with curcumin and the piperine reference substance solution (contains curcumin 0.1mgmL
-1With piperine 5 μ gmL
-1).
Get the about 20mg of compound turmeric rhizome solid dispersion, put in the 50ml volumetric flask, add dissolve with methanol and be settled to scale, shake up, accurate this solution 5ml that draws puts in the 50ml volumetric flask, adds the methanol dilution and is settled to scale, filter with microporous filter membrane (0.45 μ m), as need testing solution.Accurate respectively need testing solution and each 5 μ L of reference substance solution of drawing inject chromatograph of liquid, measure in accordance with the law.Chromatogram is 5,6,7,8,9,10 results show, adopts this chromatographic condition can determine the content of curcumin and piperine in the compound turmeric rhizome solid dispersion exactly.
The experimentation of embodiment 4 compound turmeric rhizome solid dispersion effect for reducing blood fat
4.1 material
4.1.1 medicine and reagent
Fenofibrate capsule (the French profit Fu Ni drugmaker of fighting, lot number: 80791); SHANZHAJING JIANGZHI PIAN (a Fujian remittance day biological pharmaceutcal corporation, Ltd, lot number: 20060101); Triton WR-1339 (SIGMA product, lot number: 253010204); Serum total cholesterol (TC) enzyme process test kit (glad biotechnology research institute of Shanghai section, lot number: 20060901); Serum triglycerides (TG) enzyme process test kit (glad biotechnology research institute of Shanghai section, lot number: 20060901); NaTDC (Beijing ancient cooking vessel state biotechnology Co., Ltd, lot number: DS022); Cholesterol (chemical reagent glass apparatus wholesale department, Guangzhou, lot number: 20051202); Methylthiouracil sheet (state-run Wujin, changzhou pharmaceutical factory, lot number: 021023); L-sodium glutamate (Shanghai chemical reagents corporation, lot number: F20010925); Tween (chemical reagent glass apparatus wholesale department, Guangzhou, lot number: 20060801).
4.1.2 instrument
752N type ultraviolet-uisible spectrophotometer (Shanghai Precision Scientific Apparatus Co., Ltd); SIGMA 3K30 high-speed refrigerated centrifuge (SIGMA); Sartorius BS224S ten thousand/electronic balance (Beijing Sartorius Instr Ltd.)
4.1.3 animal
The NIH mice, body weight 18～22g; The SD rat, body weight 200～220g, male and female half and half provide by Guangdong Medical Lab Animal Center.The quality certification number: mice: 2006A017, rat: 2006A015.
4.2 method
4.2.1 Triton WR-1339 is caused the influence of mice hyperlipemia
Get 84 of NIH mices, male and female half and half are divided into matched group, model group, fenofibrate group, Fructus Crataegi essence group, the basic, normal, high dosage group of compound turmeric rhizome solid dispersion at random.Each administration group is gastric infusion according to dosage, and contrast, model give the equal-volume distilled water, once a day, and continuous 3d.Respectively organize the equal overnight fasting of mice after the 2nd administration, the last administration is preceding except that matched group, all the other respectively organize the equal tail vein injection TritonWR-1339 of mice 400mg/kg modeling, the 3rd gastric infusion after the modeling, pluck eyeball behind the 4h and get blood, separation of serum is measured test kit explanation carrying out TC, TG by TC, TG and is measured.
4.2.2 influence to bait hyperlipidemia rats TC, TG
Get 70 of SD rats, male and female half and half are divided into matched group, model group, fenofibrate Capsules group at random, SHANZHAJING JIANGZHI PIAN group, the high, medium and low dosage group of compound turmeric rhizome solid dispersion.Each administration group ig administration according to dosage, contrast, model give the equal-volume distilled water, every day 1 time, continuous 4 weeks.Simultaneously, except that matched group, each treated animal all gavages lipomul 15mLkg-1, once a day, and continuous 4 weeks.Animal is weighed weekly 2 times, adjusts dosage according to body weight, finishes until experiment.The last administration and give lipomul after, water 12h is can't help in the equal fasting of all animals, weighs, and gets blood examination and surveys serum TC, TG.
4.2.3 to bait hyperlipidemia rats body weight and the exponential influence of liver
Body weight change is weekly write down, analyzed to experiment 4.2.2 animal; After the execution, get liver and weigh, calculate the liver index.
4.2.4 acute toxicity test in mice
Get 20 of NIH mices, male and female half and half are divided into 2 groups.Ig gives compound turmeric rhizome solid dispersion behind the animal fasting 12h, observes the reaction of animals situation after the administration, observes 7d continuously, the toxic reaction that the record animal may occur, and food-intake of animal and amount of drinking water.
4.3 result:
4.3.1 compound turmeric rhizome solid dispersion causes the influence of mice hyperlipemia to Triton WR-1339
Table 3 and Figure 11,12 show, compare with model group, and each dosage group mice serum content of triglyceride of compound turmeric rhizome solid dispersion, cholesterol level all significantly reduce (P＜0.01).
Table 3 compound turmeric rhizome solid dispersion causes the influence (x ± s) of mice hyperlipemia to Triton WR-1339
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01; Compare with model group,
#P＜0.05,
##P＜0.01.
4.3.2 compound turmeric rhizome solid dispersion is to the influence of rat bait hyperlipemia
Table 4 and Figure 13,14 show, compare with model group, and each dosage group rat blood serum content of triglyceride of compound turmeric rhizome solid dispersion, cholesterol level all significantly reduce (P＜0.01).
Table 4 compound turmeric rhizome solid dispersion is to the influence of rat bait hyperlipemia (x ± s)
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01; Compare with model group,
#P＜0.05,
##P＜0.01.
4.3.3 to bait hyperlipidemia rats body weight and the exponential influence of liver
Table 5 shows that matched group and each administration group rat body weight all increase with feeding time lengthening, and model group and each administration group rat body weight and matched group be there was no significant difference relatively; Compare with matched group, each modeling rat liver index all has increase, and significant difference (P＜0.01) appears in model group, fenofibrate Capsules group, compound turmeric group liver index; And compare with model group, the compound turmeric group has downward trend along with dosage increases the liver index.
Table 5 compound turmeric rhizome solid dispersion is to bait hyperlipidemia rats body weight and the exponential influence of liver (x ± s)
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01; Compare with model group,
#P＜0.05,
##P＜0.01.
4.3.4 acute toxicity testing
2h after the administration, mice peace and quiet, the movable minimizing; 7h after the administration, mice behavioral activity recover normal; Behind the 24h, the mice behavioral activity is all normal; Observe 7d continuously, mice survival condition, dietary amount, amount of drinking water all do not have obvious change, no animal dead, and this experiment mice of results suggest is 7.5gkg to the maximum tolerated dose of compound turmeric rhizome solid dispersion
-1, 535.7 times of quite clinical consumptions.
As can be seen from the test results, the chmice acute experimental hyperlipidemia TC that compound turmeric rhizome solid dispersion brings out Triton WR-1339, TG content and rat bait hyperlipemia model TC, TG had tangible reduction effect (P＜0.01), its action effect and Western medicine fenofibrate are approaching.
According to the literature, the positive drug fenofibrate is the special class lipid regulating agent of shellfish, has tangible hypolipemic function, is to use one of more hypolipidemic clinically, particularly triacylglycerol is had tangible reduction effect, but liver is obviously increased.This experiment has also confirmed this viewpoint.Data show, compound turmeric rhizome solid dispersion is when reducing TC, TG, and the liver index progressively reduces along with the increasing of dosage, does not have tangible hepatic injury effect.Experiment is also observed, and each administration group rat body weight and matched group more all do not have significant difference, and the prompting compound turmeric rhizome solid dispersion does not have obvious influence to the rat growing state.
Claims (6)
1, a kind of Chinese medicine compound turmeric rhizome solid dispersion for the treatment of hyperlipemia, it is characterized in that adopting the solvent method preparation by medicine curcumin, piperine component and water soluble polymer carrier, wherein the mass ratio of curcumin and piperine is 1: 1～500: 1, and the mass ratio of curcumin and water soluble polymer carrier is 1: 1～1: 4.
2, a kind of method for the treatment of the Chinese medicine compound turmeric rhizome solid dispersion of hyperlipemia is characterized in that being carrier by right 1 described drug component and proportioning with the water-soluble high-molecular material; Its concrete processing step: get curcumin, piperine and water soluble polymer carrier and be dissolved in organic solvent, distilling under reduced pressure is removed most of organic solvent until becoming pasty state under 25～75 ℃, pour in the stainless steel disc rapidly, 40～80 ℃ of following vacuum drying oven oven dry, obtain compound turmeric rhizome solid dispersion with the pulverizer pulverizing.
3, a kind of Chinese medicine compound turmeric rhizome solid dispersion for the treatment of hyperlipemia according to claim 1 and 2 is characterized in that described water soluble polymer carrier is polyvinylpyrrolidone (PVP), Polyethylene Glycol (PEG) 4000 and 6000, carbamide, citric acid, xylitol, chitosan (CS).
4, a kind of method for the treatment of the Chinese medicine compound turmeric rhizome solid dispersion of hyperlipemia according to claim 2 is characterized in that described organic solvent is ethanol, isopropyl alcohol, propanol or ethyl acetate.
5, a kind of Chinese medicine compound turmeric rhizome solid dispersion for the treatment of hyperlipemia according to claim 1 is characterized in that described dosage form can make injection, tablet, powder, granule, capsule, oral liquid or suppository as required.
6, a kind of purposes of Chinese medicine compound turmeric rhizome solid dispersion is characterized in that being used for the treatment of the blood fat reducing class medicine of hyperlipemia or the application in the health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101069687A CN101301455A (en) | 2008-07-01 | 2008-07-01 | Chinese medicine compound turmeric rhizome solid dispersion for treating hyperlipemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101069687A CN101301455A (en) | 2008-07-01 | 2008-07-01 | Chinese medicine compound turmeric rhizome solid dispersion for treating hyperlipemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101301455A true CN101301455A (en) | 2008-11-12 |
Family
ID=40111672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101069687A Pending CN101301455A (en) | 2008-07-01 | 2008-07-01 | Chinese medicine compound turmeric rhizome solid dispersion for treating hyperlipemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101301455A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784421A (en) * | 2014-02-27 | 2014-05-14 | 哈尔滨医科大学 | Curcumin and piperine carried solid lipid nanoparticles and preparation method thereof |
| CN106137972A (en) * | 2016-08-01 | 2016-11-23 | 杭州成邦医药科技有限公司 | A kind of solid dispersion containing curcumin and preparation method thereof |
| EA027148B1 (en) * | 2014-04-23 | 2017-06-30 | Мухаммед Маджид | Method for the treatment of hypercholesterolemia |
| CN108815121A (en) * | 2018-07-04 | 2018-11-16 | 常州大学 | A kind of Dimethylcurcumin solid dispersions and the preparation method and application thereof |
| CN111357910A (en) * | 2020-04-20 | 2020-07-03 | 江苏慧博生物科技有限公司 | Turmeric and pepper solid beverage and preparation method thereof |
| CN113827594A (en) * | 2021-10-14 | 2021-12-24 | 河南省纳普生物技术有限公司 | Scalp antibacterial and anti-inflammatory composition based on solid dispersion technology and preparation method thereof |
| CN114246279A (en) * | 2021-10-28 | 2022-03-29 | 申农(上海)生态农业发展有限公司 | Turmeric beverage and processing technology thereof |
-
2008
- 2008-07-01 CN CNA2008101069687A patent/CN101301455A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784421A (en) * | 2014-02-27 | 2014-05-14 | 哈尔滨医科大学 | Curcumin and piperine carried solid lipid nanoparticles and preparation method thereof |
| EA027148B1 (en) * | 2014-04-23 | 2017-06-30 | Мухаммед Маджид | Method for the treatment of hypercholesterolemia |
| CN106137972A (en) * | 2016-08-01 | 2016-11-23 | 杭州成邦医药科技有限公司 | A kind of solid dispersion containing curcumin and preparation method thereof |
| CN108815121A (en) * | 2018-07-04 | 2018-11-16 | 常州大学 | A kind of Dimethylcurcumin solid dispersions and the preparation method and application thereof |
| CN111357910A (en) * | 2020-04-20 | 2020-07-03 | 江苏慧博生物科技有限公司 | Turmeric and pepper solid beverage and preparation method thereof |
| CN113827594A (en) * | 2021-10-14 | 2021-12-24 | 河南省纳普生物技术有限公司 | Scalp antibacterial and anti-inflammatory composition based on solid dispersion technology and preparation method thereof |
| CN114246279A (en) * | 2021-10-28 | 2022-03-29 | 申农(上海)生态农业发展有限公司 | Turmeric beverage and processing technology thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103319479B (en) | Rhubarb yellow berberine ion-pair compound, preparation method and application | |
| Xu et al. | Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats | |
| CN101301455A (en) | Chinese medicine compound turmeric rhizome solid dispersion for treating hyperlipemia | |
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| Wu et al. | In vitro inhibition of lipid accumulation induced by oleic acid and in vivo pharmacokinetics of chitosan microspheres (CTMS) and chitosan-capsaicin microspheres (CCMS) | |
| CN103893258A (en) | Oral solid preparation containing desmodium styracifolium general flavone and application thereof | |
| CN101057674B (en) | Composition for preventing and curing diabetes | |
| CN102058822B (en) | Pharmaceutical composition for strengthening stomach and promoting digestion | |
| CN102225208B (en) | Limonene inclusion complex and preparation method thereof | |
| Wang et al. | Compatibility of Polygonati Rhizoma and Angelicae Sinensis Radix enhance the alleviation of metabolic dysfunction-associated fatty liver disease by promoting fatty acid β-oxidation | |
| WO2022237731A1 (en) | Pharmaceutical composition for treating hyperlipidemia and preparation method therefor | |
| CN104383547B (en) | Herba Saussureae Involueratae extract phosphatide complexes, oral disnitegration tablet and preparation method thereof | |
| CN102670698B (en) | The application of Radix Flemingiae Philippinensis extract in preparation control diabetes medicament | |
| Serra et al. | Dissolution efficiency and bioequivalence study using urine data from healthy volunteers: a comparison between two tablet formulations of cephalexin | |
| CN109876022B (en) | Black fungus blood fat reducing active part and preparation method and application thereof | |
| CN103159710B (en) | Antiviral decalin derivate | |
| CN112843111A (en) | Pharmaceutical composition for treating metabolism-related fatty liver disease and preparation method and application thereof | |
| CN103142597B (en) | Ipecacuanha effective component composition, its preparation method and application | |
| CN101554417B (en) | Quality control method of antitumor Chinese medicine composition | |
| US20120309700A1 (en) | Development and evaluation of novel chinese materia medica preparations | |
| CN104042613B (en) | A kind of composition and the purposes in medicine thereof | |
| CN103495156B (en) | Recombinant human insulin sustained-release tablet and preparation method thereof | |
| CN117752607A (en) | Oral micelle taking ginseng active ingredient as auxiliary material and preparation method and application thereof | |
| CN102188468B (en) | Preparation method of Xinnaoshutong tablet | |
| CN107913308A (en) | A kind of Sichuan chinaberry extract and biomedical uses using root of Beijing euphorbia alkane type triterpenoid as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081112 |